Literature DB >> 23261357

Triage of HPV-positive women in cervical cancer screening.

Nicolas Wentzensen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23261357      PMCID： PMC4198376          DOI： 10.1016/S1470-2045(12)70568-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  9 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

2.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

3.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Authors:  Philip E Castle; Mark H Stoler; Thomas C Wright; Abha Sharma; Teresa L Wright; Catherine M Behrens
Journal:  Lancet Oncol       Date:  2011-08-22       Impact factor: 41.316

4.  A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.

Authors:  Mark Schiffman; Andrew G Glass; Nicolas Wentzensen; Brenda B Rush; Philip E Castle; David R Scott; Julie Buckland; Mark E Sherman; Greg Rydzak; Peter Kirk; Attila T Lorincz; Sholom Wacholder; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05-20       Impact factor: 4.254

Review 5.  From differences in means between cases and controls to risk stratification: a business plan for biomarker development.

Authors:  Nicolas Wentzensen; Sholom Wacholder
Journal:  Cancer Discov       Date:  2013-01-08       Impact factor: 39.397

6.  Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.

Authors:  Nicolas Wentzensen; Lauren Schwartz; Rosemary E Zuna; Katie Smith; Cara Mathews; Michael A Gold; R Andy Allen; Roy Zhang; S Terence Dunn; Joan L Walker; Mark Schiffman
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

7.  Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

Authors:  Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Anna Gillio-Tos; Laura De Marco; Paolo Giorgi-Rossi; Giovanni Pontenani; Stefano Rosso; Cristina Sani; Catia Sintoni; Nereo Segnan; Manuel Zorzi; Jack Cuzick; Raffaella Rizzolo; Guglielmo Ronco
Journal:  Lancet Oncol       Date:  2008-09-08       Impact factor: 41.316

Review 8.  Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.

Authors:  Kate Cuschieri; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

9.  Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.

Authors:  Francesca Carozzi; Anna Gillio-Tos; Massimo Confortini; Annarosa Del Mistro; Cristina Sani; Laura De Marco; Salvatore Girlando; Stefano Rosso; Carlo Naldoni; Paolo Dalla Palma; Manuel Zorzi; Paolo Giorgi-Rossi; Nereo Segnan; Jack Cuzick; Guglielmo Ronco
Journal:  Lancet Oncol       Date:  2012-12-21       Impact factor: 41.316
  9 in total
  13 in total

1.  Invited Commentary: Clinical Utility of Prediction Models for Rare Outcomes--The Example of Pancreatic Cancer.

Authors:  Nicolas Wentzensen; Ronald C Eldridge
Journal:  Am J Epidemiol       Date:  2015-06-06       Impact factor: 4.897

2.  p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.

Authors:  Nicolas Wentzensen; Barbara Fetterman; Philip E Castle; Mark Schiffman; Shannon N Wood; Eric Stiemerling; Diane Tokugawa; Clara Bodelon; Nancy Poitras; Thomas Lorey; Walter Kinney
Journal:  J Natl Cancer Inst       Date:  2015-09-15       Impact factor: 13.506

3.  Filling a gap in cervical cancer screening programmes.

Authors:  Nicolas Wentzensen; Mark Schiffman
Journal:  Lancet Oncol       Date:  2014-02-13       Impact factor: 41.316

Review 4.  Meta-analysis of downregulated E-cadherin as a diagnostic biomarker for cervical cancer.

Authors:  Xiaoxia Ma; An Ge; Jie Han; Jin Kang; Yating Zhang; Xiaohong Liu; Li Xing; Xiaochun Liu; Li Dong
Journal:  Arch Gynecol Obstet       Date:  2022-03-13       Impact factor: 2.344

5.  HPV16 Down-Regulates the Insulin-Like Growth Factor Binding Protein 2 to Promote Epithelial Invasion in Organotypic Cultures.

Authors:  Adam Pickard; Simon S McDade; Marie McFarland; W Glenn McCluggage; Cosette M Wheeler; Dennis J McCance
Journal:  PLoS Pathog       Date:  2015-06-24       Impact factor: 6.823

Review 6.  Issues in optimising and standardising the accuracy and utility of the colposcopic examination in the HPV era.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  Ecancermedicalscience       Date:  2015-04-29

7.  Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a 10-year prospective cohort study.

Authors:  Li Dong; Li Zhang; Shang-Ying Hu; Rui-Mei Feng; Xue-Lian Zhao; Qian Zhang; Qin-Jing Pan; Xun Zhang; You-Lin Qiao; Fang-Hui Zhao
Journal:  Clin Epigenetics       Date:  2020-05-07       Impact factor: 6.551

8.  Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.

Authors:  Nicolas Wentzensen; Megan A Clarke; Renee Bremer; Nancy Poitras; Diane Tokugawa; Patricia E Goldhoff; Philip E Castle; Mark Schiffman; Julie D Kingery; Kiranjit K Grewal; Alex Locke; Walter Kinney; Thomas S Lorey
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

9.  Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.

Authors:  Hans Ikenberg; Christine Bergeron; Dietmar Schmidt; Henrik Griesser; Francisco Alameda; Claudio Angeloni; Johannes Bogers; Roger Dachez; Karin Denton; Jalil Hariri; Thomas Keller; Magnus von Knebel Doeberitz; Heinrich H Neumann; Luis M Puig-Tintore; Mario Sideri; Susanne Rehm; Ruediger Ridder
Journal:  J Natl Cancer Inst       Date:  2013-10-04       Impact factor: 13.506

10.  HPV in women assisted by the Family Health Strategy.

Authors:  Andréia Rodrigues Gonçalves Ayres; Gulnar Azevedo E Silva; Maria Teresa Bustamante Teixeira; Kristiane de Castro Dias Duque; Maria Lúcia Salim Miranda Machado; Carmen Justina Gamarra; José Eduardo Levi
Journal:  Rev Saude Publica       Date:  2017-10-05       Impact factor: 2.106
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.